Literature DB >> 8271296

Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol.

G L Day1, W J Blot, R E Shore, J K McLaughlin, D F Austin, R S Greenberg, J M Liff, S Preston-Martin, S Sarkar, J B Schoenberg.   

Abstract

BACKGROUND: The exceptionally high rate of second primary cancers among patients with oral and pharyngeal cancers is well recognized, yet there has been limited epidemiologic study of risk factors for second tumors.
PURPOSE: To evaluate the relation of smoking and alcohol consumption to the development of second cancers among this high-risk patient group, we conducted a nested case-control study.
METHODS: A total of 1090 patients enrolled in a 1984-1985 population-based, case-control study of oral cancer in four areas of the United States were followed through June 1989 for the occurrence of second primary cancers. Information on tobacco and alcohol consumption was obtained from the original interviews and was updated by follow-up interviews obtained for 80 case patients with second cancers and 189 sex-, study area-, and survival-matched cancer patients free of second cancers (control subjects).
RESULTS: Tobacco smoking and alcohol drinking each contributed to risk of second cancers, with the effects of smoking more pronounced than those of alcohol. The odds ratios (ORs) for smoking (adjusted for alcohol) rose with duration and intensity of smoking and were strongest for tumors of the aerodigestive tract (oral cavity, pharynx, esophagus, larynx, and lungs), with ORs reaching 4.7 (95% confidence interval [CI] = 1.4-16) among smokers of 40 or more cigarettes per day for 20 or more years. Current smokers as of the baseline survey experienced a fourfold increased risk of a second aerodigestive tract cancer relative to nonsmokers and former smokers. No reduction in risk was associated with cessation of smoking or drinking at or after the index diagnosis, although the short median interval (27 months) between tumor diagnoses limited observation of the effects due to recent cessation. Risk was significantly reduced, however, 5 years after smoking cessation. Among drinkers, second cancer risk was greatest for beer intake, with an OR for a second aerodigestive tract cancer of 3.8 (95% CI = 1.2-12) for 15 or more beers per week.
CONCLUSIONS: Oral and pharyngeal cancer patients with the highest intakes of tobacco and alcohol are the ones most prone to develop second primary cancers. IMPLICATIONS: Avoidance of tobacco smoking and alcohol drinking is the most desirable way not only to prevent primary oral cancers, but also to reduce risk of second cancers of the aerodigestive system.

Entities:  

Mesh:

Year:  1994        PMID: 8271296     DOI: 10.1093/jnci/86.2.131

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  66 in total

1.  FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Li-E Wang; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

Review 2.  Time course of risk factors in cancer etiology and progression.

Authors:  Esther K Wei; Kathleen Y Wolin; Graham A Colditz
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

3.  Smoking status and symptom burden in surgical head and neck cancer patients.

Authors:  Katherine R Sterba; Elizabeth Garrett-Mayer; Matthew J Carpenter; Janet A Tooze; Jeanne L Hatcher; Christopher Sullivan; Lee Anne Tetrick; Graham W Warren; Terrence A Day; Anthony J Alberg; Kathryn E Weaver
Journal:  Laryngoscope       Date:  2016-07-09       Impact factor: 3.325

4.  Evaluation of an intervention to enhance the delivery of smoking cessation services to patients with cancer.

Authors:  Marie-Helene Gosselin; Martin C Mahoney; K Michael Cummings; Thom R Loree; Maureen Sullivan; Brian A King; Graham Warren; Andrew Hyland
Journal:  J Cancer Educ       Date:  2011-09       Impact factor: 2.037

5.  Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck.

Authors:  Yang Zhang; Erich M Sturgis; Zhigang Huang; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer       Date:  2011-06-29       Impact factor: 6.860

6.  Establishing the predictive validity of intentions to smoke among preadolescents and adolescents surviving cancer.

Authors:  James L Klosky; Vida L Tyc; Ashley Hum; Shelly Lensing; Joanna Buscemi; Danette M Garces-Webb; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

7.  Smokeless and dual tobacco use among males surviving childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  James L Klosky; Ashley M Hum; Nan Zhang; Khatidja S Ali; D Kumar Srivastava; Robert C Klesges; Karen M Emmons; Kirsten K Ness; Marilyn Stovall; Leslie L Robison; Melissa M Hudson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-11       Impact factor: 4.254

8.  Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx.

Authors:  Susan T Mayne; Brenda Cartmel; Victoria Kirsh; W Jarrard Goodwin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

9.  Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

Review 10.  Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research.

Authors:  Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-17       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.